Skip to Main Content

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)

Conditions

Women's Health

Phase III

What is the purpose of this trial?

A Phase 3 randomized clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to placebo.

  • Trial with
    Yale University School of Medicine
  • Start Date
    12/01/2021
  • End Date
    10/31/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/28/2022
  • Study HIC
    #2000027121